📢STROKE STUDY HIGHLIGHTS – Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo – the CHIMES & CHIMES-E studies by Chen CLH, Chai JH, Pokharkar YM, and Venketasubramanian N.

We are pleased to share our recent work on the cost-effectiveness of NeuroAiD in improving functional recovery after stroke! The study compares NeuroAiD on top of standard stroke care with standard stroke care only for patients from a large randomised placebo-controlled clinical trial, the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) and its extension (CHIMES-E).

Key findings reveal:
💰Potential cost-savings of €5,080 and a gain of 0.45 QALYs.
👍Similar dominance (cost-savings and gain in QALYs) observed in subgroups with poor-prognosis factors.

Read the full study on: https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-024-11618-4. Chen, C.L.H., Chai, J.H., Pokharkar, Y.M. et al. Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo – the CHIMES & CHIMES-E studies. BMC Health Serv Res 24, 1127 (2024). This article is licensed under a CC-BY license.